Emerging studies suggest this peptide, a dual agonist targeting both GLP-1 and another hormone, may provide a significant advancement for weight treatment. Early clinical trials have indicated considerable decreases in visceral mass , conceivably exceeding other weight-loss medications . However , more assessment is needed to completely determine i